Zacks Investment Research upgraded shares of Selecta Biosciences, Inc. (NASDAQ:SELB) from a hold rating to a buy rating in a report issued on Saturday. The firm currently has $10.00 price target on the stock.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Several other brokerages also recently commented on SELB. Canaccord Genuity upped their price target on shares of Selecta Biosciences from $25.00 to $30.00 and gave the company a buy rating in a report on Thursday, October 12th. ValuEngine downgraded shares of Selecta Biosciences from a hold rating to a sell rating in a report on Tuesday, September 26th. Finally, UBS AG downgraded shares of Selecta Biosciences from a buy rating to a neutral rating in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Selecta Biosciences has an average rating of Buy and an average price target of $25.20.
Selecta Biosciences (NASDAQ:SELB) opened at $8.97 on Friday. Selecta Biosciences has a fifty-two week low of $8.70 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. The company had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative net margin of 1,918.59% and a negative return on equity of 100.06%. sell-side analysts forecast that Selecta Biosciences will post -2.25 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Selecta Biosciences, Inc. (SELB) Raised to Buy at Zacks Investment Research” was published by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/14/selecta-biosciences-inc-selb-raised-to-buy-at-zacks-investment-research.html.
In related news, Director Timothy C. Barabe bought 5,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were acquired at an average cost of $9.37 per share, for a total transaction of $46,850.00. Following the purchase, the director now directly owns 4,992 shares of the company’s stock, valued at $46,775.04. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Amir Nashat sold 42,610 shares of the company’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $20.03, for a total transaction of $853,478.30. The disclosure for this sale can be found here. Insiders sold a total of 355,658 shares of company stock worth $6,955,732 over the last 90 days. Insiders own 41.90% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Nationwide Fund Advisors grew its stake in Selecta Biosciences by 224.5% in the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after acquiring an additional 4,561 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Selecta Biosciences by 827.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after acquiring an additional 10,040 shares in the last quarter. Rhumbline Advisers bought a new position in Selecta Biosciences in the 2nd quarter worth about $239,000. New York State Common Retirement Fund grew its stake in Selecta Biosciences by 184.0% in the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after acquiring an additional 8,099 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Selecta Biosciences in the 1st quarter worth about $211,000. Institutional investors and hedge funds own 53.03% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.